Prevnar 20 (pneumococcal 20-valent conjugate vaccine) / Pfizer - LARVOL DELTA

A Study to Assess the Safety, Tolerability, and Immunogenicity of 3 Lots of a Multivalent Pneumococcal Conjugate Vaccine Administered to Adults (clinicaltrials.gov) - P3 | N=4670 | Recruiting | Sponsor: Pfizer | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Pneumococcal Infections

Pneumococcal serotype distribution and diagnostic yield of serotype-specific urinary antigen detection in adults with CAP in Switzerland, 2016-2021: a prospective cohort study. (PubMed, BMC Infect Dis) - "The addition of ssUAD improved S. pneumoniae detection beyond standard methods. Although based on a small number of cases, the shift toward non-PCV13 serotypes underscores the potential benefit of higher-valency vaccines such as PCV20 and PCV21 for adult pneumococcal disease prevention in Switzerland."

Journal • Infectious Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases

20-valent pneumococcal conjugate vaccine: Impact and effectiveness against all-cause outcomes among the general population of US older adults by age group, regardless of prior pneumococcal vaccine history (IDWeek 2026) - No abstract available

Clinical • Pneumococcal vaccines • Infectious Disease • Pneumococcal Infections

Number Needed to Vaccinate for Pediatric Pneumococcal Conjugate Vaccines: How Dynamic Transmission Modeling Reshapes Comparative Estimates for PCV20 and PCV15 (IDWeek 2026) - No abstract available

Clinical • Infectious Disease • Pneumococcal Infections

Early Trends for Invasive Pneumococcal Disease in Children After the Introduction of the 20-valent Pneumococcal Conjugate Vaccine (IDWeek 2026) - No abstract available

Clinical • Infectious Disease • Pneumococcal Infections

A Study of V132 in Healthy Older Participants (V132-001) (clinicaltrials.gov) - P1 | N=280 | Recruiting | Sponsor: Merck Sharp & Dohme LLC | Not yet recruiting ➔ Recruiting

Enrollment open

A Study to Assess the Safety, Tolerability, and Immunogenicity of 3 Lots of a Multivalent Pneumococcal Conjugate Vaccine Administered to Adults (clinicaltrials.gov) - P3 | N=4670 | Not yet recruiting | Sponsor: Pfizer

New P3 trial • Infectious Disease • Pneumococcal Infections

A Study to Evaluate 20vPnC in Healthy Chinese Infants (clinicaltrials.gov) - P3 | N=1250 | Recruiting | Sponsor: Pfizer

New P3 trial • Infectious Disease • Pneumococcal Infections

Community-Acquired Pneumonia Incidence in Adults Aged 18 Years and Older in Goto City, Japan: A Prospective Population-Based Study. (PubMed, CHEST Pulm) - "Applying Goto's incidence and case fatality rate to the Japanese population, assuming PCV20 has the same vaccine efficacy and duration of protection as PCV13 and if licensed in Japan for the prevention of CAP, the inclusion of PCV20 in the national immunization program for adults ≥ 65 years of age could prevent 29,036 cases of CAP and 2,275 CAP-related deaths per year. Given the substantial burden of preventable pneumococcal disease, introduction of pneumococcal conjugate vaccines in Japanese adults may be of merit."

Journal • Infectious Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases

Vaccine Responses in Patients With B Cell Malignancies (clinicaltrials.gov) - P4 | N=350 | Recruiting | Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Trial completion date: Aug 2026 ➔ Nov 2036 | Trial primary completion date: Aug 2026 ➔ Nov 2036

Trial completion date • Trial primary completion date • Chronic Lymphocytic Leukemia • Hematological Malignancies • Lymphoma • Oncology • BCL2

Pneumococcal community-acquired pneumonia in hospitalized adults in México 2018-2021: serotype distribution and clinical characteristics. (PubMed, Front Public Health) - "During the study period, CAP was associated with a substantial mortality burden among hospitalized adult patients in México, with pCAP more frequent among high-risk patients. These findings underscore the needs for enhanced diagnostic approaches and risk group-targeted adult pneumococcal vaccination programs."

Journal • Infectious Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases

A Study of V132 in Healthy Older Participants (V132-001) (clinicaltrials.gov) - P1 | N=280 | Not yet recruiting | Sponsor: Merck Sharp & Dohme LLC

New P1 trial

Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in the 20-Valent Pneumococcal Conjugate Vaccine in the Adult Population in France. (PubMed, Open Forum Infect Dis) - "This study models the burden of adult pneumococcal disease in France. Over a 5-year period, approximately 630 000 cases and €3.1 billion of costs were attributable to pneumococcus, mostly noninvasive disease, with nearly 80% due to serotypes included in 20-valent pneumococcal conjugate vaccine."

HEOR • Journal • Infectious Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases

Vaccine Responses in Patients With B Cell Malignancies (clinicaltrials.gov) - P4 | N=350 | Recruiting | Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | N=500 ➔ 350

Enrollment change • Chronic Lymphocytic Leukemia • Hematological Malignancies • Lymphoma • Oncology • BCL2

A Study of V118E in Healthy Participants (V118E-003) (clinicaltrials.gov) - P1 | N=126 | Recruiting | Sponsor: Merck Sharp & Dohme LLC | Trial completion date: Nov 2027 ➔ Jul 2027 | Trial primary completion date: Nov 2027 ➔ Jul 2027

Trial completion date • Trial primary completion date

Estimating clinical and economic impacts and cost-effectiveness of introducing 20-valent pneumococcal conjugate vaccine in Taiwan's pediatric National Immunization Program and impacts of a delayed implementation. (PubMed, Hum Vaccin Immunother) - "Delaying PCV20 introduction resulted in substantial losses, with a 1-y delay causing over 3,200 additional cases and exceeding NT$40 million in forgone savings, doubling with a 2-y delay. Implementing PCV20 in Taiwan's pediatric NIP is projected to improve health outcomes and reduce costs, while delays in implementation would lead to significantly avoidable losses compared with PCV13- or PCV15-based programs."

HEOR • Journal • Infectious Disease • Pediatrics • Pneumococcal Infections

Projected health and economic impact of PCV20 vaccination in UK children: a dynamic transmission model. (PubMed, Expert Rev Vaccines) - "Sensitivity and scenario results were consistent with the base-case. Pediatric PCV20 implementation in the UK could deliver substantial health gains while improving economic efficiency."

HEOR • Journal • Infectious Disease • Novel Coronavirus Disease • Pediatrics • Pneumococcal Infections

Cost effectiveness and public health impact of PCV20 among adults in France. (PubMed, BMC Public Health) - "PCV20 is a cost-saving alternative to the PCV13 → PPV23 sequence for at-risk adults in France. Expanding recommendations to include all adults aged 65 years and over provides substantial public health gains and represents a highly cost-effective strategy."

HEOR • Journal • CNS Disorders • Infectious Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases

Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and Adolescents (clinicaltrials.gov) - P3 | N=1200 | Recruiting | Sponsor: Pfizer

New P3 trial • Infectious Disease • Pneumococcal Infections

A Study to Learn About How a New Pneumococcal Vaccine Works in Children (clinicaltrialsregister.eu) - P2 | N=225 | Sponsor: Pfizer, Inc

New P2 trial • Dermatology • Infectious Disease • Pneumococcal Infections • Pneumonia

Safety and Immunogenicity of 20-valent Pneumococcal Conjugate Vaccine According to Number and Timing of Primary Series Doses. (PubMed, Pediatr Infect Dis J) - "In this descriptive analysis of the 2 + 1 schedule, a 1-month delay in PCV20 priming to 3 and 5 months was associated with improved immune responses comparable to those of PCV13 at 2 and 4 months."

Journal • Infectious Disease • Pneumococcal Infections

A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in Adults (clinicaltrials.gov) - P1/2 | N=1363 | Completed | Sponsor: Pfizer | Active, not recruiting ➔ Completed | N=558 ➔ 1363

Enrollment change • Trial completion • Infectious Disease • Pneumococcal Infections

Estimated pneumococcal disease burden in children due to serotypes covered by different pneumococcal conjugate vaccines in five Latin American countries. (PubMed, Front Pediatr) - "Despite the success of PCV10 and PCV13 in reducing pneumococcal disease in Latin America, a considerable clinical, economic, and societal burden remains due to serotypes included in higher-valent vaccines. Broader serotype coverage offered by PCV20 has the potential to address this unmet burden and further reduce the public health and economic impact of pneumococcal disease in young children across the region."

Journal • Infectious Disease • Otorhinolaryngology • Pediatrics • Pneumococcal Infections • Pneumonia • Respiratory Diseases

Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants from Approximately 2 Months of Age (clinicaltrialsregister.eu) - P3 | N=1630 | Sponsor: Sanofi Pasteur Inc.

New P3 trial • Dermatology • Infectious Disease • Pneumococcal Infections

A Study to Learn About How a New Pneumococcal Vaccine Works in Infants. (clinicaltrials.gov) - P3 | N=3230 | Recruiting | Sponsor: Pfizer

New P3 trial • Infectious Disease • Pneumococcal Infections